Recent ICON Paper Points to Higher-Than Expected Impact of ICER Assessments

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2GLoEzR on April 30, 2019 at 04:56PM

A recent paper by ICON suggests the Institute for Clinical and Economic Review’s (ICER) drug assessments carry more weight in decision-making among payers than originally expected, according to an article published on Forbes.

The white paper, titled “Industry Perceptions and Expectations: The Role of ICER as an Independent HTA Organisation,” also offers a look at how much the U.S. health system could potentially save if organizations were to implement prices based off ICER’s recommendations.

“Through all of this research, we noted that ICER’s impact and influence on payer decision making is higher than initially expected, which in retrospect is not surprising considering the speed at which ICER has made itself a household name in our industry,” the white paper states.

To read more on Forbes, click here.

Click here to learn how to download ICON’s paper.